AstraZeneca (AZN) Partnered with DPS Group in Sweden for Construction Contract

The UK researched-based biopharmaceutical company, AstraZeneca PLC (NYSE:AZN) partnered with DPS Group, the global and European based engineering, consulting and project management company, in a construction contract.

The contract is specific for AstraZeneca’s pharmaceutical site in Swedan.

The terms and condition of contract was not disclosed by both companies even the value, however, DPs Group said that it will provide Engineering, Procurement, Construction Management and Validation (EPCMV) services for all small and medium projects of AstraZeneca’s site in Swedan.

DPS Group serving to their clients with lean construction experience in pharmaceuticals, biotech, medical devices and semiconductors from over 40 years in US and Europe. With over 1,300 employees, the construction firm presently serving their customers in Ireland, Netherlands, Belgium, Sweden, Israel, Singapore, Switzerland, the United Kingdom and the United States.

After winning the construction contract from AstraZeneca’s, DPS Group said that it is now building its office in Swedan completely for AstraZeneca which will provide services to AstraZeneca on starting and later on for other clients.

“DPS are delighted to have won this contract and we are confident the combination of a substantial local office and local partners in Sweden, as well as our large pharma center of excellence offices in Dublin and Cork will ensure a quality and cost-effective delivery model for AstraZeneca. As with all our clients we will work with AstraZeneca in a true partnership, building a long-term relationship.” CEO of DPS Group, Frank Keogh, commented on the winning contract from AsrtaZeneca (AZN).

However, in other news for AstraZeneca, the biotech firm said that it will published its financial results for the first quarter of 2018 on Friday, May 18, 2018 on its website at 07:00 UK time.

A webcast for the financial results also will take place at 12:00 UK time on Friday, May 18, 2018.

With the $90.69 market value, AstraZeneca PLC (NYSE:AZN)’s shares up 0.05% or $0.02 cents to close the Monday trading session at $36.42. The biotech company posted EPS of $1.18 for the trailing twelve months.